Homeostatic imbalance between cell proliferation and death in gastric mucosal epithelia may lead to gastritis and gastric cancer. Despite abundant gastrokine 1 (GKN1) expression in the normal stomach, the loss of GKN1 expression is frequently detected in gastric mucosa infected with Helicobacter pylori, as well as in intestinal metaplasia and gastric cancer tissues, suggesting that GKN1 plays an important role in gastric mucosal defense, and the gene functions as a gastric tumor suppressor. In the stomach, GKN1 is involved in gastric mucosal inflammation by regulating cytokine production, the nuclear factor-κB signaling pathway, and cyclooxygenase-2 expression. GKN1 also inhibits the carcinogenic potential of H. pylori protein CagA by binding to it, and up-regulates antioxidant enzymes. In addition, GKN1 reduces cell viability, proliferation, and colony formation by inhibiting cell cycle progression and epigenetic modification by down-regulating the expression levels of DNMT1 and EZH2, and DNMT1 activity, and inducing apoptosis through the death receptordependent pathway. Furthermore, GKN1 also inhibits gastric cancer cell invasion and metastasis via coordinated regulation of epithelial mesenchymal transition-related protein expression, reactive oxygen species production, and PI3K/Akt signaling pathway activation. Although the modes of action of GKN1 have not been clearly described, recent limited evidence suggests that GKN1 acts as a gastricspecific tumor suppressor. This review aims to discuss, comment, and summarize the recent progress in the understanding of the role of GKN1 in gastric cancer development and progression.
Introduction
Generally, the gastrointestinal epithelium is characterized by a very high cellular turnover rate, which leads to renewal of the epithelium every 3 to 5 days. 1 Continuous processes of cell proliferation, differentiation, and self-renewal are counterbalanced by senescence and/or apoptosis in normal gastric mucosa. To maintain homeostasis, a critical balance between cell proliferation and death is required, and complex signaling pathways and transcriptional regulators control it. Otherwise, homeostatic imbalance, caused by several factors, including infection with Helicobacter pylori, ingested noxious agents, and acidic pH, may lead to diseases such as gastritis and gastric cancer. Therefore, protective and reparative mechanisms are essential to rapidly restore gastric mucosal integrity by stimulating migration of epithelial cells over denuded areas (restitution), increasing mucus production, and reestablishing epithelial proliferation and differentiation programs. 2 Although endogenous molecules, such as members of the trefoil factor 1 protein family, protect the gastric mucosa from noxious environments, 3 many of their underlying molecular mechanisms have not been clearly elucidated.
Gastrokine 1 (GKN1), also called antral mucosal protein (AMP)-18, is a protein synthesized by the cells of the antral gastric mucosa and shows growth factor or 'cytokine-like' activity toward gastric epithelial cells. 4 Immunoelectron microscopy indicated that the GKN1 protein is localized within the granules just under the apical plasma membrane, suggesting that it is a secreted rather than an integral membrane protein. 4 Early work reported that Two isoforms of the GKN1 protein with different NH 2 -terminal residues, aspartic acid (D) and asparagine (N), were found in gastric endoscopy biopsy samples, and the isoform containing asparagine was decreased or absent in some H. pylori-positive patients. 13 Therefore, these two isoforms might play different roles in H. pylori-infected gastric mucosa. Previously, we reported that an aspartic acid or asparagine variant at codon 13 in the NH 2 -terminal region, but not alanine variant of the pGKN1 D13A mutant, was found to be important in the anti-growth function of GKN1. 12 Therefore, it seems that genetic alterations or loss of expression of the NH 2 -terminal hydrophobic region and BRICHOS domain of GKN1 might lead to the functional inactivation of the GKN1
protein. However, to explain how GKN1 expression is controlled in normal gastric mucosa, further studies are important to delineate the molecular mechanisms regulating transcription and biological roles of GKN1 in gastric mucosal epithelia.
Gastrokine 1 in Non-Neoplastic Gastric Mucosa
GKN1 is a unique gastric-specific protein, whose expression is confined to the gastric epithelium, except for trace levels in the uterus and placenta. 5 GKN1 protein and mRNA are localized in surface mucous cells of the gastric antrum and fundus in humans. 6, [13] [14] [15] [16] GKN1 is involved in filling the lumen of the surface layer of epithelial cells to maintain mucosal integrity and regulate cell proliferation and differentiation. 5, 6 In addition, GKN1 is present in the secretion granules of gastric mucosal epithelial cells during immunogold-labeling experiments 4 and, therefore, is predicted to function as a secreted protein acting primarily in the extracellular and luminal environment. 9 As mentioned earlier, the gastrointestinal epithelium is characterized by a very high cellular turnover rate, which leads to renewal of the epithelium every 3 to 5 days.
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GKN1 also facilitates regeneration of the injured colonic epithelium by accelerating migration of surviving cells at the edges of wounds, and also stimulating cell proliferation to resurface the injured mu-cosa after cell detachment, apoptosis, and necrosis. 4, 5 However, subsequent studies have reported that overexpression of GKN1 inhibits cell proliferation and induces Fas-mediated apoptosis and senescence through p16/Rb pathway activation in gastric epithelial cells. [16] [17] [18] [19] Although the molecular mechanisms that explain these opposite effects of GKN1 in colon and gastric epithelial cells remain unclear, it is possible that GKN1 might inhibit or stimulate cell growth in a cell type-specific and context-dependent manner.
Therefore, more work is needed to better understand the bioactivity of GKN1 in maintaining the homeostasis of normal gastric mucosa.
Generally, gastric mucosal inflammation is believed to be caused tor-α production. 21, 22 In addition to the role of cytokine production, aberrant activation of NF-κB leads to cell growth and resistance to apoptosis in gastric cancer cells. 23, 24 Interestingly, ectopic GKN1 expression was found to suppress the activation and nuclear translocation of NF-κB by inhibiting degradation and phosphorylation of NF-κB specific inhibitor (IκB) and inactivating IKKα/β in AGS gastric cancer cells (Fig. 1 ). 25 Furthermore, GKN1 induces a significant increase in the expression of IL-17, but markedly decreases the expression of IL-6, IL-10, and cyclooxygenase-2 (COX-2), which are correlated with tumor progression and serve as independent predictors of poor survival in gastric cancer (Fig. 1) . [25] [26] [27] [28] The IL-17 family of cytokines performs numerous immune regulatory functions related to local tissue inflammation by inducing and mediating proinflammatory responses. 29 IL-17 acts upon gastric epithelial cells to release IL-8, which recruits neutrophils, 30 and is associated with prolonged survival in gastric cancer patients. 31 In contrast, IL-10 is an anti-inflammatory cytokine that suppresses the production of pro-inflammatory cytokines through the inhibition of Th1 lymphocytes and stimulation of B and Th2 lymphocytes, in order to down-regulate the inflammatory response. 32 In particular, IL-6
is generally considered to be a pro-inflammatory and pleiotropic cytokine involved in tumor initiation, promotion, and progression. 33 COX-2 expression in the injured mucosa plays a significant role in the repair processes and defense mechanisms of the stomach. 34 COX-2 inhibition has been shown to suppress cell proliferation and induce apoptosis in many gastrointestinal cancer cell lines. 35 Therefore, these findings imply that GKN1 may play an important role in gastric mucosal inflammation by mediating cytokine production and suppression of NF-κB and COX-2, thereby contributing to the maintenance of gastric mucosal homeostasis.
It has been reported that H. pylori infection and long-term
non-steroidal anti-inflammatory drug administration down-regulate the expression of GKN1 in gastric mucosal epithelial cells. 15, 36 In accordance with these observations, the GKN1 mRNA transcript was strongly up-regulated in the gastric transcriptome after H. pylori eradication and cessation of gastritis. 37 Previously, we also found that the presence of H. pylori CagA was inversely correlated with GKN1 expression in non-neoplastic gastric mucosa. 38 Furthermore, the expression of GKN1 was significantly reduced in the cases with H. pylori CagA positivity, mononuclear cell infiltration, atrophy, and intestinal metaplasia. In addition, GKN1 predicted the risk of atrophy and intestinal metaplasia with an area under the receiver operating characteristic curve value of 0.865 and 0.973, respectively. 38 Taken together, these findings provide evidence that the expression levels of GKN1 might be a predictive and diagnostic biomarker for evaluating the severity of gastritis and CagA-positive H. pylori infection.
GKN2, also known as TFIZ1 and Blottin, is expressed in surface pit cells in both the corpus and antrum, and are thought to be secreted. 8, [39] [40] [41] GKN2 gene expression was shown to be significantly reduced in AGS and KATO-III gastric adenocarcinoma cell lines by the p50 and p65 subunits of NF-κB, and co-transfection with
IκB resulted in up-regulation of the GKN2 gene. 2 Interestingly, GKN2 alone did not affect cell viability, whereas co-transfection with GKN1 and GKN2 in vitro showed that GKN2 inhibited the effect of GKN1 on cell viability, proliferation, and apoptosis by down-regulating miR-185 expression and inducing epigenetic modification. Furthermore, the expression of GKN2 was regulated in a GKN1-dependent manner by inactivating the NF-κB signaling pathway. 42 Therefore, GKN2 might play an important role in gastric mucosal homeostasis by regulating GKN1 activities. These data agree with the previous findings that GKN2 did not induce any significant effects in the cell wounding assay in HGT-101 gastric cancer cells. 40 However, GKN2 expression was also reduced in H.
pylori-infected gastritis 37 and gastric cancers. 43, 44 Moreover, GKN2
decreased cell growth in SGC-7901 gastric cancer cells in vitro. 43 A recent study confirmed that GKN2 inhibits proliferation, migration, and invasion of gastric cancer cells, and arrests the cell cycle at the G1/S transition phase, 44 prompting recognition of GKN2 as a putative stomach-specific tumor suppressor gene and implying its potential use in gastric cancer therapy. While the basis of these controversial results is unclear, we speculate that GKN2 might suppress gastric cancer cell growth, but inhibit GKN1-induced cell death to maintain homeostasis in normal gastric mucosa. Further efforts to clarify the molecular mechanisms underlying GKN2 functions will provide more comprehensive information about the use of GKN2 in anticancer or mucosal protective therapeutics.
Gastrokine 1 in the Development of Gastric Cancer
GKN1 mRNA is one of the most abundant transcripts in the normal gastric mucosa, accounting for approximately 1% of total gastric mRNA. 45 Interestingly, it was demonstrated that individuals with a lower expression of GKN1 have an increased risk of developing gastric disease. 14 Numerous studies have described frequent reduction or complete loss of GKN1 expression in gastric tumors, including adenomas and adenocarcinomas. 6, 7, 15, 16 Loss of GKN1 expression in gastric cancer was first described in differential display analysis. 46 In immunohistochemical analysis, loss of GKN1 expres- Chronic infection with H. pylori perpetuates chronic gastritis, which progresses to mucosal atrophy, intestinal metaplasia, dysplasia, and carcinoma. 50 As described above, GKN1 expression is down-regulated in H. pylori-infected gastric mucosal tissue. 13, 15, 36, 37 These observations invoke the hypothesis that H. pylori infection might regulate the expression of GKN1 protein. In recognition of this possibility, we analyzed the effects of H. pylori CagA on GKN1 expression in gastric epithelial cells. Interestingly, H. pylori
CagA-induced reactive oxygen species (ROS) reduced the expression of the GKN1 protein by decreasing GKN1 DNA and mRNA copy numbers in gastric cell lines and mucosal tissues of humans and mice. 51 As shown in Fig. 1 , the ectopic expression of GKN1
inhibited CagA-induced ROS production and GKN1 copy number change via overexpression of antioxidant enzymes, MnSOD, and catalase. In addition, GKN1 prevented the injection of CagA into cells by binding to CagA at the extracellular level, 51 suggesting that GKN1 may counteract the CagA-induced genetic alterations.
These results were corroborated by those of Moss and colleagues, 14 who reported that individuals with a lower expression of GKN1
have an increased risk of developing gastric cancer. Therefore, it is expected that the presence of GKN1 helps to maintain the homeostasis of normal gastric mucosa, even if H. pylori infection exists.
In contrast, inactivation of the GKN1 gene may lead to a defect in the gastric mucosal barrier, rendering gastric mucosa subject to exposure to carcinogens, including H. pylori CagA, and eventually evoke subsequent genetic alterations of tumor suppressor genes or oncogenes involved in gastric carcinogenesis.
Gastrokine 1 in the Progression of Gastric Cancer
Epithelial mesenchymal transition (EMT) is a normal physi- plasticity. 53 Unfortunately, most gastric cancer patients are diagnosed at the advanced stages of the disease, which contribute to the high lethality rate in the world. 54 The identification of signals that lead to EMT and cancer cell migration remains a central challenge in cancer research, and a better understanding of the molecular mechanisms of invasion and metastasis of gastric cancer may provide new insight and information to develop novel therapeutic targets for treatment of gastric cancer patients.
As described above, turning epithelial cancer cells into mesenchymal cells was proposed to be the critical process for the acquisition of the invasive and metastatic phenotype of epithelial cancer cells during tumor progression. Previously, it was reported that ROS stimulated EMT, 55 and the activation of PI3K/Akt signaling was detected in cells undergoing EMT. 56 Our subsequent study found that GKN1 induced the conversion of spindle-shaped cells with abundant cytoplasms to circular-shaped cells, and suppressed suggest that GKN1 may inhibit gastric carcinogenesis through the induction of miR-185, thereby modulating epigenetic alterations in cell cycle regulatory components.
Regarding cell death, ectopic expression of GKN1 in AGS gastric cancer cells induced activation of the apoptosis-related proteins, including cleaved caspase-8, caspase-3, and poly-(ADP-ribose)
polymerase, whereas no change in expression of the mitochondrial pathway-related proteins was observed (Fig. 1) . 16 Thus, we conclude that GKN1 may induce apoptosis via the death receptor-mediated, Thus, it is plausible that modulating GKN1 activity and stimulating its anti-cancerous effects could significantly influence the development of novel cancer therapeutics, which would ultimately achieve the goal of gastric cancer prevention and remission. Future studies to clarify the biological activity and regulatory mechanisms of GKN1 will be pivotal to develop GKN1 as a potential therapeutic target for gastric cancer patients.
